Deep Learning Models Compared to Experimental Variability for the Prediction of CYP3A4 Time-Dependent Inhibition

Most drugs are mainly metabolized by cytochrome P450 (CYP450), which can lead to drug–drug interactions (DDI). Specifically, time-dependent inhibition (TDI) of CYP3A4 isoenzyme has been associated with clinically relevant DDI. To overcome potential DDI issues, high-throughput in vitro assays were es...

Full description

Saved in:
Bibliographic Details
Published inChemical research in toxicology Vol. 37; no. 4; pp. 549 - 560
Main Authors Fluetsch, Andrin, Trunzer, Markus, Gerebtzoff, Grégori, Rodríguez-Pérez, Raquel
Format Journal Article
LanguageEnglish
Published United States American Chemical Society 15.04.2024
Subjects
Online AccessGet full text

Cover

Loading…
Abstract Most drugs are mainly metabolized by cytochrome P450 (CYP450), which can lead to drug–drug interactions (DDI). Specifically, time-dependent inhibition (TDI) of CYP3A4 isoenzyme has been associated with clinically relevant DDI. To overcome potential DDI issues, high-throughput in vitro assays were established to assess the TDI of CYP3A4 during the discovery and lead optimization phases. However, in silico machine learning models would enable an earlier and larger-scale assessment of TDI potential liabilities. For CYP inhibition, most modeling efforts have focused on highly imbalanced and small data sets. Moreover, assay variability is rarely considered, which is key to understand the model’s quality and suitability for decision-making. In this work, machine learning models were built for the prediction of TDI of CYP3A4, evaluated prospectively, and compared to the variability of the experimental assay. Different modeling strategies were investigated to assess their influence on the model’s performance. Through multitask learning, additional data sets were leveraged for model building, coming from public databases, in-house CYP-related assays, or other pharmaceutical companies (federated learning). Apart from the numerical prediction of inactivation rates of CYP3A4 TDI, three-class predictions were carried out, giving a negative (inactivation rate k obs < 0.01 min–1), weak positive (0.01 ≤ k obs ≤ 0.025 min–1), or positive (k obs > 0.025 min–1) output. The final multitask graph neural network model achieved misclassification rates of 8 and 7% for positive and negative TDI, respectively. Importantly, the presented deep learning-based predictions had a similar precision to the reproducibility of in vitro experiments and thus offered great opportunities for drug design, early derisk of DDI potential, and selection of experiments. To facilitate CYP inhibition modeling efforts in the public domain, the developed model was used to annotate ∼16 000 publicly available structures, and a surrogate data set is shared as Supporting Information.
AbstractList Most drugs are mainly metabolized by cytochrome P450 (CYP450), which can lead to drug-drug interactions (DDI). Specifically, time-dependent inhibition (TDI) of CYP3A4 isoenzyme has been associated with clinically relevant DDI. To overcome potential DDI issues, high-throughput in vitro assays were established to assess the TDI of CYP3A4 during the discovery and lead optimization phases. However, in silico machine learning models would enable an earlier and larger-scale assessment of TDI potential liabilities. For CYP inhibition, most modeling efforts have focused on highly imbalanced and small data sets. Moreover, assay variability is rarely considered, which is key to understand the model's quality and suitability for decision-making. In this work, machine learning models were built for the prediction of TDI of CYP3A4, evaluated prospectively, and compared to the variability of the experimental assay. Different modeling strategies were investigated to assess their influence on the model's performance. Through multitask learning, additional data sets were leveraged for model building, coming from public databases, in-house CYP-related assays, or other pharmaceutical companies (federated learning). Apart from the numerical prediction of inactivation rates of CYP3A4 TDI, three-class predictions were carried out, giving a negative (inactivation rate kobs < 0.01 min-1), weak positive (0.01 ≤ kobs ≤ 0.025 min-1), or positive (kobs > 0.025 min-1) output. The final multitask graph neural network model achieved misclassification rates of 8 and 7% for positive and negative TDI, respectively. Importantly, the presented deep learning-based predictions had a similar precision to the reproducibility of in vitro experiments and thus offered great opportunities for drug design, early derisk of DDI potential, and selection of experiments. To facilitate CYP inhibition modeling efforts in the public domain, the developed model was used to annotate ∼16 000 publicly available structures, and a surrogate data set is shared as Supporting Information.
Most drugs are mainly metabolized by cytochrome P450 (CYP450), which can lead to drug-drug interactions (DDI). Specifically, time-dependent inhibition (TDI) of CYP3A4 isoenzyme has been associated with clinically relevant DDI. To overcome potential DDI issues, high-throughput assays were established to assess the TDI of CYP3A4 during the discovery and lead optimization phases. However, machine learning models would enable an earlier and larger-scale assessment of TDI potential liabilities. For CYP inhibition, most modeling efforts have focused on highly imbalanced and small data sets. Moreover, assay variability is rarely considered, which is key to understand the model's quality and suitability for decision-making. In this work, machine learning models were built for the prediction of TDI of CYP3A4, evaluated prospectively, and compared to the variability of the experimental assay. Different modeling strategies were investigated to assess their influence on the model's performance. Through multitask learning, additional data sets were leveraged for model building, coming from public databases, in-house CYP-related assays, or other pharmaceutical companies (federated learning). Apart from the numerical prediction of inactivation rates of CYP3A4 TDI, three-class predictions were carried out, giving a negative (inactivation rate < 0.01 min ), weak positive (0.01 ≤ ≤ 0.025 min ), or positive ( > 0.025 min ) output. The final multitask graph neural network model achieved misclassification rates of 8 and 7% for positive and negative TDI, respectively. Importantly, the presented deep learning-based predictions had a similar precision to the reproducibility of experiments and thus offered great opportunities for drug design, early derisk of DDI potential, and selection of experiments. To facilitate CYP inhibition modeling efforts in the public domain, the developed model was used to annotate ∼16 000 publicly available structures, and a surrogate data set is shared as Supporting Information.
Most drugs are mainly metabolized by cytochrome P450 (CYP450), which can lead to drug–drug interactions (DDI). Specifically, time-dependent inhibition (TDI) of CYP3A4 isoenzyme has been associated with clinically relevant DDI. To overcome potential DDI issues, high-throughput in vitro assays were established to assess the TDI of CYP3A4 during the discovery and lead optimization phases. However, in silico machine learning models would enable an earlier and larger-scale assessment of TDI potential liabilities. For CYP inhibition, most modeling efforts have focused on highly imbalanced and small data sets. Moreover, assay variability is rarely considered, which is key to understand the model’s quality and suitability for decision-making. In this work, machine learning models were built for the prediction of TDI of CYP3A4, evaluated prospectively, and compared to the variability of the experimental assay. Different modeling strategies were investigated to assess their influence on the model’s performance. Through multitask learning, additional data sets were leveraged for model building, coming from public databases, in-house CYP-related assays, or other pharmaceutical companies (federated learning). Apart from the numerical prediction of inactivation rates of CYP3A4 TDI, three-class predictions were carried out, giving a negative (inactivation rate k obs < 0.01 min–1), weak positive (0.01 ≤ k obs ≤ 0.025 min–1), or positive (k obs > 0.025 min–1) output. The final multitask graph neural network model achieved misclassification rates of 8 and 7% for positive and negative TDI, respectively. Importantly, the presented deep learning-based predictions had a similar precision to the reproducibility of in vitro experiments and thus offered great opportunities for drug design, early derisk of DDI potential, and selection of experiments. To facilitate CYP inhibition modeling efforts in the public domain, the developed model was used to annotate ∼16 000 publicly available structures, and a surrogate data set is shared as Supporting Information.
Author Trunzer, Markus
Fluetsch, Andrin
Gerebtzoff, Grégori
Rodríguez-Pérez, Raquel
Author_xml – sequence: 1
  givenname: Andrin
  surname: Fluetsch
  fullname: Fluetsch, Andrin
– sequence: 2
  givenname: Markus
  surname: Trunzer
  fullname: Trunzer, Markus
– sequence: 3
  givenname: Grégori
  surname: Gerebtzoff
  fullname: Gerebtzoff, Grégori
– sequence: 4
  givenname: Raquel
  orcidid: 0000-0002-2992-3402
  surname: Rodríguez-Pérez
  fullname: Rodríguez-Pérez, Raquel
  email: raquel.rodriguez_perez@novartis.com
BackLink https://www.ncbi.nlm.nih.gov/pubmed/38501689$$D View this record in MEDLINE/PubMed
BookMark eNqFkMtOwzAQRS0EgvL4BeQlm5Sx3byWqDylIrooCFaR7UyoUWIHO5XK3-OqBZasZnPuHd1zTPats0jIOYMxA84upQ5jvcTOYxjceiw0gIB0j4xYyiFJgcE-GUFRioTz4vWIHIfwAcBiNj8kR6KIRFaUI9JfI_Z0htJbY9_po6uxDXTqul56rOng6M26R286tINs6Yv0RirTmuGLNs7TYYl0HkGjB-MsdQ2dvs3F1YQuYiK5xh5tHZP0wS6NMhvmlBw0sg14trsn5Pn2ZjG9T2ZPdw_Tq1kiJ8CHJMWs4aoBiXVeN6CYyBXTEiaqyEFgnnKe6bQsiiznUgnWYF0KybBgSiuFtTghF9ve3rvPVbRUdSZobFtp0a1Cxcu4n4ssFRHNtqj2LgSPTdXHwdJ_VQyqje0q2q7-bFc72zF4vvuxUh3Wv7EfvRHgW2BT8OFW3sbJ_7V-A3KUlB8
CitedBy_id crossref_primary_10_1038_s41467_024_49979_3
crossref_primary_10_1021_acs_molpharmaceut_3c01124
Cites_doi 10.1038/srep42717
10.26434/chemrxiv-2022-ntd3r
10.1021/ci200028n
10.1017/S0033583515000190
10.1053/cp.1999.v66.a101461
10.1021/acs.jcim.9b00801
10.1021/acs.molpharmaceut.2c00571
10.1021/acs.jcim.7b00088
10.2174/156802606778108951
10.1186/s13321-020-0414-z
10.1124/dmd.105.006874
10.1093/nar/gkr777
10.1016/j.patter.2023.100804
10.1021/acs.jcim.9b00237
10.1016/j.ailsci.2021.100027
10.1109/JPROC.2015.2494218
10.1021/acs.molpharmaceut.2c00680
10.1021/tx700079z
10.1021/acs.jcim.5b00130
10.1021/ci400084k
10.1021/acs.jcim.8b00785
10.1214/ss/1177013815
10.1021/ci200091h
10.1080/1062936X.2017.1399925
10.1021/ci200311w
10.1021/ci200615h
10.1001/jama.287.17.2215
10.1093/nar/gkac956
10.1007/s40262-019-00750-8
10.3109/03602532.2014.1003648
10.1177/1087057104274091
10.1124/dmd.110.037911
10.1016/j.ailsci.2022.100056
10.1007/s10822-005-9013-3
10.1021/acs.jcim.2c00412
10.1016/j.slasd.2024.01.005
10.1016/j.bmc.2021.116388
10.1007/s00216-008-2291-6
10.1517/17425255.3.1.51
10.1023/A:1010933404324
10.1021/mp0700413
ContentType Journal Article
Copyright 2024 American Chemical Society
Copyright_xml – notice: 2024 American Chemical Society
DBID CGR
CUY
CVF
ECM
EIF
NPM
AAYXX
CITATION
7X8
DOI 10.1021/acs.chemrestox.3c00305
DatabaseName Medline
MEDLINE
MEDLINE (Ovid)
MEDLINE
MEDLINE
PubMed
CrossRef
MEDLINE - Academic
DatabaseTitle MEDLINE
Medline Complete
MEDLINE with Full Text
PubMed
MEDLINE (Ovid)
CrossRef
MEDLINE - Academic
DatabaseTitleList MEDLINE - Academic
MEDLINE

Database_xml – sequence: 1
  dbid: NPM
  name: PubMed
  url: https://proxy.k.utb.cz/login?url=http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed
  sourceTypes: Index Database
– sequence: 2
  dbid: EIF
  name: MEDLINE
  url: https://proxy.k.utb.cz/login?url=https://www.webofscience.com/wos/medline/basic-search
  sourceTypes: Index Database
DeliveryMethod fulltext_linktorsrc
Discipline Public Health
Pharmacy, Therapeutics, & Pharmacology
EISSN 1520-5010
EndPage 560
ExternalDocumentID 10_1021_acs_chemrestox_3c00305
38501689
d122875611
Genre Journal Article
GroupedDBID ---
-~X
29B
4.4
55A
5GY
5RE
5VS
7~N
AABXI
ABJNI
ABMVS
ABQRX
ABUCX
ACGFS
ACJ
ACS
ADHLV
AEESW
AENEX
AFEFF
AGXLV
AHGAQ
ALMA_UNASSIGNED_HOLDINGS
AQSVZ
BAANH
CS3
CUPRZ
EBS
ED~
F5P
GGK
GNL
IH9
IHE
JG~
LG6
P2P
ROL
TN5
UI2
UPT
VF5
VG9
W1F
YZZ
CGR
CUY
CVF
ECM
EIF
NPM
AAYXX
CITATION
7X8
ID FETCH-LOGICAL-a402t-5e6f2bf0aed7df0b137b1ca04b8703e75226c5988672ab31fed93a1e81bcbbed3
IEDL.DBID ACS
ISSN 0893-228X
IngestDate Sat Aug 17 05:40:31 EDT 2024
Wed Sep 25 14:11:36 EDT 2024
Sat Nov 02 12:31:38 EDT 2024
Fri Sep 20 10:05:55 EDT 2024
IsDoiOpenAccess false
IsOpenAccess true
IsPeerReviewed true
IsScholarly true
Issue 4
Language English
LinkModel DirectLink
MergedId FETCHMERGED-LOGICAL-a402t-5e6f2bf0aed7df0b137b1ca04b8703e75226c5988672ab31fed93a1e81bcbbed3
Notes ObjectType-Article-1
SourceType-Scholarly Journals-1
ObjectType-Feature-2
content type line 23
ORCID 0000-0002-2992-3402
OpenAccessLink https://pubs.acs.org/doi/pdf/10.1021/acs.chemrestox.3c00305
PMID 38501689
PQID 2968923653
PQPubID 23479
PageCount 12
ParticipantIDs proquest_miscellaneous_2968923653
crossref_primary_10_1021_acs_chemrestox_3c00305
pubmed_primary_38501689
acs_journals_10_1021_acs_chemrestox_3c00305
PublicationCentury 2000
PublicationDate 2024-04-15
PublicationDateYYYYMMDD 2024-04-15
PublicationDate_xml – month: 04
  year: 2024
  text: 2024-04-15
  day: 15
PublicationDecade 2020
PublicationPlace United States
PublicationPlace_xml – name: United States
PublicationTitle Chemical research in toxicology
PublicationTitleAlternate Chem. Res. Toxicol
PublicationYear 2024
Publisher American Chemical Society
Publisher_xml – name: American Chemical Society
References ref9/cit9
ref45/cit45
ref6/cit6
ref36/cit36
ref3/cit3
ref27/cit27
ref18/cit18
ref11/cit11
ref25/cit25
ref16/cit16
ref29/cit29
ref32/cit32
ref23/cit23
ref39/cit39
ref14/cit14
ref8/cit8
ref5/cit5
ref31/cit31
ref2/cit2
ref43/cit43
ref34/cit34
ref37/cit37
ref28/cit28
ref40/cit40
ref20/cit20
ref17/cit17
ref10/cit10
ref26/cit26
ref35/cit35
ref19/cit19
ref21/cit21
ref12/cit12
ref15/cit15
ref42/cit42
ref46/cit46
ref41/cit41
ref22/cit22
ref13/cit13
ref33/cit33
ref4/cit4
ref30/cit30
ref47/cit47
ref1/cit1
ref24/cit24
ref38/cit38
ref44/cit44
ref7/cit7
References_xml – ident: ref42/cit42
  doi: 10.1038/srep42717
– ident: ref38/cit38
  doi: 10.26434/chemrxiv-2022-ntd3r
– ident: ref17/cit17
  doi: 10.1021/ci200028n
– ident: ref37/cit37
– ident: ref11/cit11
  doi: 10.1017/S0033583515000190
– ident: ref9/cit9
  doi: 10.1053/cp.1999.v66.a101461
– ident: ref20/cit20
  doi: 10.1021/acs.jcim.9b00801
– ident: ref24/cit24
  doi: 10.1021/acs.molpharmaceut.2c00571
– ident: ref27/cit27
  doi: 10.1021/acs.jcim.7b00088
– ident: ref5/cit5
  doi: 10.2174/156802606778108951
– ident: ref12/cit12
  doi: 10.1186/s13321-020-0414-z
– ident: ref45/cit45
  doi: 10.26434/chemrxiv-2022-ntd3r
– ident: ref32/cit32
– ident: ref7/cit7
  doi: 10.1124/dmd.105.006874
– ident: ref43/cit43
  doi: 10.1093/nar/gkr777
– ident: ref33/cit33
– ident: ref22/cit22
  doi: 10.1016/j.patter.2023.100804
– ident: ref36/cit36
  doi: 10.1021/acs.jcim.9b00237
– ident: ref26/cit26
  doi: 10.1016/j.ailsci.2021.100027
– ident: ref35/cit35
  doi: 10.1109/JPROC.2015.2494218
– ident: ref40/cit40
  doi: 10.1021/acs.molpharmaceut.2c00680
– ident: ref1/cit1
  doi: 10.1021/tx700079z
– ident: ref34/cit34
– ident: ref16/cit16
  doi: 10.1021/acs.jcim.5b00130
– ident: ref23/cit23
  doi: 10.1021/ci400084k
– ident: ref28/cit28
  doi: 10.1021/acs.jcim.8b00785
– ident: ref30/cit30
  doi: 10.1214/ss/1177013815
– ident: ref14/cit14
  doi: 10.1021/ci200091h
– ident: ref15/cit15
  doi: 10.1080/1062936X.2017.1399925
– ident: ref18/cit18
  doi: 10.1021/ci200311w
– ident: ref25/cit25
  doi: 10.1021/ci200615h
– ident: ref39/cit39
– ident: ref8/cit8
  doi: 10.1001/jama.287.17.2215
– ident: ref44/cit44
  doi: 10.1093/nar/gkac956
– ident: ref3/cit3
  doi: 10.1007/s40262-019-00750-8
– ident: ref2/cit2
  doi: 10.3109/03602532.2014.1003648
– ident: ref19/cit19
  doi: 10.1177/1087057104274091
– ident: ref10/cit10
  doi: 10.1124/dmd.110.037911
– ident: ref46/cit46
  doi: 10.1016/j.ailsci.2022.100056
– ident: ref47/cit47
  doi: 10.1007/s10822-005-9013-3
– ident: ref41/cit41
  doi: 10.1021/acs.jcim.2c00412
– ident: ref29/cit29
  doi: 10.1016/j.slasd.2024.01.005
– ident: ref21/cit21
  doi: 10.1016/j.bmc.2021.116388
– ident: ref4/cit4
  doi: 10.1007/s00216-008-2291-6
– ident: ref6/cit6
  doi: 10.1517/17425255.3.1.51
– ident: ref31/cit31
  doi: 10.1023/A:1010933404324
– ident: ref13/cit13
  doi: 10.1021/mp0700413
SSID ssj0011027
Score 2.4777896
Snippet Most drugs are mainly metabolized by cytochrome P450 (CYP450), which can lead to drug–drug interactions (DDI). Specifically, time-dependent inhibition (TDI) of...
Most drugs are mainly metabolized by cytochrome P450 (CYP450), which can lead to drug-drug interactions (DDI). Specifically, time-dependent inhibition (TDI) of...
SourceID proquest
crossref
pubmed
acs
SourceType Aggregation Database
Index Database
Publisher
StartPage 549
SubjectTerms Cytochrome P-450 CYP3A - metabolism
Cytochrome P-450 Enzyme System - metabolism
Deep Learning
Drug Interactions
Models, Biological
Reproducibility of Results
Title Deep Learning Models Compared to Experimental Variability for the Prediction of CYP3A4 Time-Dependent Inhibition
URI http://dx.doi.org/10.1021/acs.chemrestox.3c00305
https://www.ncbi.nlm.nih.gov/pubmed/38501689
https://search.proquest.com/docview/2968923653
Volume 37
hasFullText 1
inHoldings 1
isFullTextHit
isPrint
link http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwlZ3fb9MwEMdPY7wgIX4MGOWXDgnthaWL7diJH6du00ACFbGh8hTlYochIKmWVKL89dhxuoJQBbxGsuVczvHHPt_3AF4YVcRUCRYZ4U-rjNQRZZpHypCRiigRfYb3m7fq9Dx5PZOzLYg3RPA5OyhKZ_wL-82Xqmi-j0XZY-81uM5Thw8ehibvr-IGrkXQ9tQi4jybrXKCN_bjF6Wy_X1R2kCa_YpzchverfJ2wkWTL-NFR-Pyx58yjv_8Mnfg1oCfeBj85S5s2XoH9qZBv3q5j2frdKx2H_dwula2Xu7AzXDIhyF36R7Mj6yd4yDR-gl9XbWvLU6Ga-3YNXj8SwEB_OD25UEWfImOldGxJ04vfaTIewc2FU4-TsVhgj4vJToayvN2-Kq--Ez91bL7cH5yfDY5jYYSDlHhNqZdJK2qOFVxYU1qqpiYSImVRZyQ-08Im3r6K6XOMpXyggSrrNGiYNbBdElkjXgA23VT24eAXis-TstYGlU5BpSkmayMtUInKVmejOCls24-TME276PrnOX-4drk-WDyERysvng-D7oef23xfOUYuZuCPq5S1LZZtDnXyrm3UFKMYDd4zFWfIpMOqjP96L9G9xhucAdPPmrF5BPY7i4X9qmDn46e9f7-ExktAvQ
link.rule.ids 315,782,786,2767,27083,27931,27932,56745,56795
linkProvider American Chemical Society
linkToHtml http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwnV3dT9swED8xeNikaRvsg-6LmzTxMlJiO3bix6qACgNUaWXqnqI4dgbaSCqSSpS_fnaStgMJTePVkq2zc5f72Xf3O4DPWiS-yhjxNHOvVZpLT0WSekIrzYVSAasrvE9OxeAsOBrzcft04WphrBClXamsg_hLdgGy68bsNi5dx4riusvSGv0-gjUuwsDl8vX63xbhAzujofiUzKM0Gs9Lg-9dx_mmtLztm-4BnLXjOXgO44XIdb7Jr-60Ut305g6b4wP29AKetWAUe432rMOKyTdge9iwWc92cLQszip3cBuHS57r2QY8bZ78sKlkegmTPWMm2BK2_kTXZe13if02yR2rAvf_aieA3-0tvSEJn6FFzmiRKA6vXNzI6QoWGfZ_DFkvQFel4u21zXorPMzPL1SdaPYKzg72R_2B1zZ08BJ7Ta08bkRGVeYnRoc68xVhoSJp4gfK_jWYCR0WTLmMIhHSRDGSGS1ZQoyF1qlSRrPXsJoXudkEdMzxfpj6XIvMIkKuJOGZNobJIFSGBh34Yk83bg2yjOtYOyWxG1weedweeQd25x8-njQsH_-c8WmuH7E1SBdlSXJTTMuYSmGVnQnOOvCmUZzFmiziFmJH8u1_SbcFjwejk-P4-PD06zt4Qi2scvEswt_DanU1NR8sLKrUx9oE_gBQSAth
linkToPdf http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwnV3ri9QwEB_OE0QQH-drfY4g98XrXpM0aYOflt1b7nwcBe9kD4TSNImK2i7XLrj-9SZtd1eFQ_RrIGGSznR-ycz8BuC5FnmoLCOBZv61SnMZqETSQGiluVAqYm2F99tjcXgavZrx2Ra8XNXCOCFqt1LdBvG9Vc-17RkGyL4fd1v55rtWVN-HrGgR8CW4zEUsfT7faPxuHUJwMzqaT8kCSpPZqjz4wnW8fyrq3_3TBaCzdT7TG_BhLXabc_JluGjUsPjxB6Pjf-7rJlzvQSmOOi26BVum3IHdtGO1Xu7hyaZIq97DXUw3fNfLHbjWPf1hV9F0G-YTY-bYE7d-RN9t7WuN4z7ZHZsKD35pK4Dv3W29IwtfokPQ6BAppuc-fuR1BiuL47OUjSL01SrBpG_a2-BR-emzahPO7sDp9OBkfBj0jR2C3F1Xm4AbYamyYW50rG2oCIsVKfIwUu7vwUzsMWHBZZKImOaKEWu0ZDkxDmIXShnN7sJ2WZXmPqBnkA_jIuRaWIcMuZKEW20Mk1GsDI0G8MKdbtYbZp21MXdKMj-4OfKsP_IB7K8-fjbv2D7-OuPZSkcyZ5g-2pKXplrUGZXCKT0TnA3gXqc86zVZwh3UTuSDf5LuKVxJJ9PszdHx64dwlTp05cNahD-C7eZ8YR47dNSoJ60V_ATWXA3k
openUrl ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fsummon.serialssolutions.com&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&rft.genre=article&rft.atitle=Deep+Learning+Models+Compared+to+Experimental+Variability+for+the+Prediction+of+CYP3A4+Time-Dependent+Inhibition&rft.jtitle=Chemical+research+in+toxicology&rft.au=Fluetsch%2C+Andrin&rft.au=Trunzer%2C+Markus&rft.au=Gerebtzoff%2C+Gr%C3%A9gori&rft.au=Rodr%C3%ADguez-P%C3%A9rez%2C+Raquel&rft.date=2024-04-15&rft.issn=0893-228X&rft.eissn=1520-5010&rft.volume=37&rft.issue=4&rft.spage=549&rft.epage=560&rft_id=info:doi/10.1021%2Facs.chemrestox.3c00305&rft.externalDBID=n%2Fa&rft.externalDocID=10_1021_acs_chemrestox_3c00305
thumbnail_l http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/lc.gif&issn=0893-228X&client=summon
thumbnail_m http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/mc.gif&issn=0893-228X&client=summon
thumbnail_s http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/sc.gif&issn=0893-228X&client=summon